SCHEMBL4839503

SCHEMBL4839503

CC(=O)Nc1cccc(-c2c(Cl)cnc3[nH]c(-c4ccc(OCCN5CCOCC5)cc4)nc23)c1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TBK1 Q9UHD2 4/20 0.53
IKBKE Q14164 1/20 0.53
EGFR P00533 3/20 0.49
ACHE P22303 2/20 0.47
ADORA2A P29274 2/20 0.46
ADORA1 P30542 2/20 0.46
ADORA3 P0DMS8 1/20 0.46
ADORA2B P29275 1/20 0.46
DHODH Q02127 1/20 0.46
SRC P12931 1/20 0.46
JAK3 P52333 1/20 0.45
BTK Q06187 1/20 0.45
RET P07949 1/20 0.44
BRAF P15056 1/20 0.44
MAPK14 Q16539 1/20 0.44
KDR P35968 1/20 0.44
EPHX2 P34913 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4834880 0.86 TBK1 (0.57) TBK1IKBKEACHEADORA2AADORA1
SCHEMBL4839489 0.82 TBK1 (0.60) TBK1IKBKEACHEADORA2AADORA1
SCHEMBL5256590 0.81 DHODH (0.40) DHODHSRCBRAF
SCHEMBL4841987 0.79 TBK1 (0.56) TBK1IKBKEACHEADORA2AADORA1
SCHEMBL4841957 0.79 TBK1 (0.64) TBK1IKBKEACHEADORA2AADORA1
SCHEMBL4838086 0.78 TBK1 (0.63) TBK1IKBKEACHEADORA2AADORA1
SCHEMBL5255272 0.78 TBK1 (0.55) TBK1IKBKEEGFRACHEADORA2A
SCHEMBL4842152 0.78 TBK1 (0.73) TBK1IKBKEEGFRACHEADORA2A
SCHEMBL4838927 0.76 TBK1 (0.58) TBK1IKBKEEGFRACHEADORA2A
SCHEMBL5256596 0.75 DHODH (0.38) DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7410966-B2 Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2008-08-12 US claimed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP claimed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US claimed
EP-1539759-A1 USE OF AND SOME NOVEL IMIDAZOPYRIDINES AstraZeneca AB (SE) 2005-06-15 EP claimed
WO-2004016611-A1 USE OF AND SOME NOVEL IMIDAZOPYRIDINES ASTRAZENECA AB (SE) 2004-02-26 WO claimed
US-7410966-B2 Use of and some novel imidazopyridines ASTRAZENECA AB (SE) 2008-08-12 US disclosed
EP-1539759-B1 NOVEL IMIDAZOPYRIDINES AND THEIR USE ASTRAZENECA AB (SE) 2007-08-15 EP disclosed
US-20050261333-A1 Use of and some novel imidazopyridines ASTRAZENECA A B (SE) 2005-11-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050261333-A1 Use of and some novel imidazopyridines ITK, CSNK1A1, RPS6KA1 TBK1 1029/4885IKBKE 95/4885EGFR 2326/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.